



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/28382/2013

European Medicines Agency decision

P/0013/2013

of 23 January 2013

on the agreement of a paediatric investigation plan and on the granting of a deferral for apixaban (Eliquis) (EMA-000183-PIP02-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0013/2013

of 23 January 2013

on the agreement of a paediatric investigation plan and on the granting of a deferral for apixaban (Eliquis) (EMA-000183-PIP02-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Bristol-Myers Squibb / Pfizer EEIG on 9 March 2012 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 7 December 2012, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for apixaban (Eliquis), film-coated tablet, oral liquid, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for apixaban (Eliquis), film-coated tablet, oral liquid, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Bristol-Myers Squibb / Pfizer EEIG, Bristol-Myers Squibb House Uxbridge Business Park, Sanderson Road, UB8 1 DH Uxbridge, United Kingdom.

Done at London, 23 January 2013

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/668161/2012

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMA-000183-PIP02-12

Scope of the application

Active substance(s):

Apixaban

Invented name:

Eliquis

Condition(s):

Treatment of venous thromboembolism

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Film-coated tablet

Oral liquid

Route(s) of administration:

Oral use

Name / corporate name of the PIP applicant:

Bristol-Myers Squibb / Pfizer EEIG

Information about the authorised medicinal product:

See Annex II



Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Bristol-Myers Squibb / Pfizer EEIG submitted for agreement to the European Medicines Agency on 9 March 2012 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 16 April 2012.

Supplementary information was provided by the applicant on 14 September 2012. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
- to grant a deferral in accordance with Article 21 of said Regulation.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

London, 7 December 2012

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

Not applicable.

2. Paediatric Investigation Plan

2.1. Condition: Treatment of venous thromboembolism

2.1.1. Indication(s) targeted by the PIP

Treatment of venous thromboembolism.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Film-coated tablet for oral use.

Oral liquid for oral use.

2.1.4. Measures

Area	Number of measures	Description
Quality	0	Not applicable.
Non-clinical	0	Not applicable.
Clinical	1	Measure 1 Open-label, multi-centre, randomized, active controlled trial to provide PK data and data on anti-Xa activity to support the extrapolation of efficacy to children, to evaluate safety and efficacy of apixaban in children (full term neonates to less than 18 years of age) who require anticoagulation for a venous thromboembolism.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By August 2020
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Prevention of venous thromboembolism

Authorised indication(s):

- Prevention of venous thromboembolic events in patients who have undergone elective hip or knee replacement surgery.

2. Prevention of arterial thromboembolism

Authorised indication(s):

- Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age $\geq$ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class $\geq$ II).

Authorised pharmaceutical formulation(s):

Film-coated tablet

Authorised route(s) of administration:

Oral use